Back to Search Start Over

Genetic variants and expression of the TIM-3 gene are associated with clinical prognosis in patients with epithelial ovarian cancer.

Authors :
Wu, Jian-Lei
Zhao, Jian
Zhang, Hai-Bo
Zuo, Wei-Wei
Li, Yan
Kang, Shan
Source :
Gynecologic Oncology. Oct2020, Vol. 159 Issue 1, p270-276. 7p.
Publication Year :
2020

Abstract

Polymorphisms of T cell immunoglobulin and mucin domain-containing molecule 3 (TIM-3) were reported to be associated with cancer risk and patients' survival. This study aims to investigate the correlation of TIM-3 polymorphisms with susceptibility to epithelial ovarian cancer (EOC) and patients' outcomes. A total of 700 EOC patients and 710 healthy controls from North China were included. The polymorphisms (rs10053538, rs10515746 and rs1036199) were genotyped using the polymerase chain reaction/ligase detection reaction (PCR-LDR) method. Survival data were available for 339 patients after cytoreductive surgery. The expression level of TIM-3 was detected by real-time quantitative PCR (RT-qPCR). The prognostic value of TIM3 in EOC patients was assessed using the Kaplan-Meier plotter database. The results showed that none of the TIM3 polymorphisms were associated with the risk of developing EOC. Patients with the rs10053538 CA + AA genotype had worse PFS and OS than those with the CC genotype (HR = 1.49, 95% CI = 1.05–2.09, P = 0.024 and HR = 1.57, 95%CI = 1.09–2.26, P = 0.017, respectively). The RT-qPCR results showed that the expression levels of TIM-3 mRNA in EOC tissues with the rs10053538CA + AA genotypes were significantly higher than those with the CC genotype (P = 0.006). Analysis using the Kaplan-Meier plotter database showed that high expression of TIM-3 mRNA was significantly associated with shorter PFS and OS in EOC patients (HR = 1.57, 95%CI = 1.29–1.91, P < 0.001 and HR = 1.31, 95% CI = 1.06–1.63, P = 0.013, respectively). TIM-3 polymorphisms were not associated with risk of developing EOC. Both rs10053538 and the expression level of TIM-3 mRNA may be associated with its clinical outcome in EOC patients. • TIM-3 polymorphisms were not associated with risk of developing EOC. • rs10053538 polymorphisms may affect the outcome in EOC patients. • The rs10053538 CA + AA genotypes may upregulate the expression of TIM-3 in EOC tissues. • Overexpression of TIM-3 mRNA was associated with poor clinical outcomes in EOC patients. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
00908258
Volume :
159
Issue :
1
Database :
Academic Search Index
Journal :
Gynecologic Oncology
Publication Type :
Academic Journal
Accession number :
146146697
Full Text :
https://doi.org/10.1016/j.ygyno.2020.07.012